<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03932279</url>
  </required_header>
  <id_info>
    <org_study_id>XZ05212018</org_study_id>
    <nct_id>NCT03932279</nct_id>
  </id_info>
  <brief_title>Characterization of the Microbiome in Cutaneous T Cell Lymphoma</brief_title>
  <official_title>Characterization of the Microbiome in Cutaneous T Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators plan to perform a pilot study that aims to characterize the microbiome of human
      cutaneous T cell lymphoma patients and compare this to the microbiome of age and sex matched
      controls.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bacterial diversity index</measure>
    <time_frame>3 months</time_frame>
    <description>Diversity analysis of microbiome samples (measured by number of bacteria species/sample)</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Cutaneous T Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Stage IA-IIA cutaneous T cell lymphoma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage IIB and above cutaneous T cell lymphoma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>CD30+ lymphoproliferative disorders</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Plaque psoriasis with BSA&gt;5% on routine phototherapy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate to severe atopic dermatitis on routine bleach bath</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cutaneous T cell lymphoma, atopic dermatitis, and psoriasis and healthy
        individuals without any of these conditions will be enrolled at Northwestern Memorial
        Hospital Dermatology outpatient clinic.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Group 1: Patients with stage IA-IIA cutaneous T cell lymphoma

          -  Group 2: Patients with stage IIB and above cutaneous T cell lymphoma

          -  Group 3: Patients with CD30+ lymphoproliferative disorder including lymphomatoid
             papulosis and cutaneous anaplastic large cell lymphoma

          -  Group 4: Patients with plaque psoriasis with BSA&gt;5% on routine phototherapy per
             standard of care

          -  Group 5: Patients with moderate to severe atopic dermatitis on routine bleach bath
             therapy per standard of care

          -  Group 6: Healthy individuals without the above skin conditions, similar age and sex
             distribution to the patients with cutaneous T cell lymphoma

          -  All Groups: subjects who are age 18-89 years of age at time of enrollment

          -  All Groups: Subjects who are able and willing to give informed consent for this study
             and the Dermatology Tissue Acquisition and Biorepository (STU00009443).

        Exclusion Criteria:

          -  All Groups: Subjects who are younger than 18 years of age or older than 90 years of
             age

          -  All Groups: Subjects who are unable to give consent

          -  Patients currently on systemic antibiotics or recent (within past 4 weeks) exposure to
             systemic antibiotics

          -  We will not recruit the following populations: adults unable to consent, individuals
             who are not yet adults (infants, children, teenagers), pregnant women, prisoners and
             other vulnerable populations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Zhou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dermatology CTU</last_name>
    <phone>312-503-5944</phone>
    <email>NUdermatologyCTU@northwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermatology CTU</last_name>
      <phone>312-503-5944</phone>
      <email>NUdermatologyCTU@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Alan Zhou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 18, 2019</study_first_submitted>
  <study_first_submitted_qc>April 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2019</study_first_posted>
  <last_update_submitted>April 28, 2019</last_update_submitted>
  <last_update_submitted_qc>April 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Xiaolong (Alan) Zhou</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

